You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,409,997

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,409,997

Title:	Functionalized graphene substrates
Abstract:	The present invention is generally directed to functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention provides a graphene substrate. The substrate comprises edge and non-edge regions, and organic or inorganic molecules are bound to the edge regions of the substrate. The organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm.
Inventor(s):	McKinney; Jeffrey Alan (Lafayette, CA), Martinez; William Emerson (Berkeley, CA)
Assignee:	Nanotech Biomachines, Inc. (Berkeley, CA)
Application Number:	14/120,485
Patent Claims:	1. A graphene substrate, wherein the substrate comprises edge and non-edge regions, and wherein organic or inorganic molecules are bound to a nucleophilic moiety covalently linked to a carbon molecule in the edge regions of the substrate, and wherein the organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm. 2. The graphene substrate according to claim 1, wherein organic molecules are present on the substrate, and wherein the organic molecules are selected from a group consisting of: antibodies; antibody fragments; aptamers; large molecule therapeutics; oligonucleotides; oligopeptides; oligopeptides, proteins and small molecule therapeutics. 3. The graphene substrate according to claim 2, wherein the population is greater than about 10 molecules per 10,000 nm. 4. The graphene substrate according to claim 3, wherein the organic molecules are selected from a group consisting of: antibodies; antibody fragments; proteins; and, aptamers. 5. The graphene substrate according to claim 3, wherein the organic molecules are selected from a group consisting of: large molecule therapeutics; oligonucleotides; oligopeptides; oligopeptides and small molecule therapeutics. 6. The graphene substrate according to claim 4, wherein the population is greater than about 50 molecules per 10,000 nm.sup.2. 7. The graphene substrate according to claim 5, wherein the population is greater than about 50 molecules per 10,000 nm.sup.2. 8. The graphene substrate according to claim 6, wherein the organic molecules are proteins, and wherein the proteins are selected from a group consisting of: Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco-cerebrosidase; Alglucosidase-.alpha.; Laronidase; Idursulphase; Galsulphase; Agalsidase-.beta.; A-1-Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin-.alpha.; Filgrastim; Sargramostim; Oprelvekin; Human follicle-stimulating hormone; Human chorionic gonadotropin; Lutropin-.alpha.; Type I .alpha.-interferon; Interferon-.alpha.2a; Interferon-.alpha.2b; Interferon-.alpha.n3; Interferon-.beta.1a; Interferon-.beta.1; Interferon-.gamma.1; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VIIa; Drotrecogin-.alpha.; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin-.alpha.; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab. 9. A method of functionalizing a graphene substrate, wherein the method comprises the steps of: a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the edge regions comprise carboxylic acid moieties, epoxy moieties or hydroxyl moieties; b) reacting the carboxylic acid moieties, epoxy moieties or hydroxyl moieties with a Nu-M, wherein Nu is a nucleophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. 10. The method according to claim 9, wherein edge regions comprise carboxylic acids. 11. The method according to claim 9, wherein Nu is NH.sub.2, and wherein M is an attached organic moiety, and wherein the organic moiety is selected from a group of organic moieties consisting of: an antibody; a linking group attached to an antibody; an antibody fragment; a linking group attached to an antibody fragment; a linking group attached to an aptamer; a protein; a linking group attached to a protein; an oligopeptide; a linking group attached to an oligopeptide; a linking group attached to an oligosaccharide; a large molecule therapeutic; a linking group attached to a large molecule therapeutic; a small molecule therapeutic; a linking group attached to a small molecule therapeutic. 12. The method according to claim 11, wherein the organic molecule is a linking group attached to a protein, and wherein the protein is selected from a group consisting of: Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco-cerebrosidase; Alglucosidase-.alpha.; Laronidase; Idursulphase; Galsulphase; Agalsidase-.beta.; A-1-Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin-.alpha.; Filgrastim; Sargramostim; Oprelvekin; Human follicle-stimulating hormone; Human chorionic gonadotropin; Lutropin-.alpha.; Type I .alpha.-interferon; Interferon-.alpha.2a; Interferon-.alpha.2b; Interferon-.alpha.n3; Interferon-.beta.1a; Interferon-.beta.1b; Interferon-.gamma.1; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VIIa; Drotrecogin-.alpha.; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin-.alpha.; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab. 13. The method according to claim 12, wherein the functionalized graphene substrate has a population of organic molecules at the edge region of at least 1 per 10,000 nm. 14. The method according to claim 13, wherein the functionalized graphene substrate has a population of organic molecules at the edge region of at least 50 per 10,000 nm.

Details for Patent 9,409,997

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974	⤷ Try a Trial	2033-05-24
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984	⤷ Try a Trial	2033-05-24
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985	⤷ Try a Trial	2033-05-24
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990	⤷ Try a Trial	2033-05-24
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974	⤷ Try a Trial	2033-05-24
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973	⤷ Try a Trial	2033-05-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.